Novo Nordisk’s obesity drug Wegovy has shown promising results in treating metabolic dysfunction steatohepatitis (MASH), a prevalent fatty liver disease affecting over 250 million people worldwide. The drug, which contains semaglutide, has demonstrated improvement in liver fibrosis and resolution of fatty liver disease in a Phase 3 clinical trial. Novo Nordisk plans to seek approval for MASH treatment in the U.S. and EU next year. While the results are seen as a significant step forward, analysts believe a combination of drugs will likely be needed to effectively treat MASH and its associated comorbidities. Other pharmaceutical companies are also developing treatments for MASH, indicating a growing trend in using GLP-1 receptor agonists for this condition.
Source link
Novo Nordisk GLP-1 Drug Meets Goals of MASH Trial, Setting Stage for FDA & EMA Filings
